阿戈美拉汀联合心理社会咨询治疗儿童青少年重性抑郁障碍的安全性与疗效:一项在九国开展的双盲随机对照3期试验
这项在九国46个精神科中心开展的12周双盲随机对照3期试验纳入400例7-17岁重性抑郁障碍患者,比较阿戈美拉汀10mg/日、25mg/日、安慰剂及氟西汀的疗效与安全性。25mg/日阿戈美拉汀组CDRS-R原始分较安慰剂组改善4.22分(95%CI 0.63-7.82;p=0.040),该效应在青少年中确认但未在儿童中确认,未观察到非预期安全信号。
要点
- 25mg/日阿戈美拉汀联合心理社会咨询较安慰剂显著改善12周CDRS-R评分。
- 总体效应在青少年中确认,在儿童中未确认。
- 未观察到非预期安全信号,无显著体重增加或自杀行为影响。
核心结论
- 该首次在儿童青少年人群开展的研究支持25mg/日阿戈美拉汀联合心理社会咨询治疗青少年重性抑郁障碍的疗效,且未观察到非预期安全信号。
- 作者认为该药可为有限的儿童青少年精神药物选择提供另一种选项。
研究设计与样本
- 12周随机、双盲、平行组、多中心3期试验,在保加利亚、芬兰、匈牙利、波兰、罗马尼亚、俄罗斯、塞尔维亚、南非和乌克兰的46个专科精神科病房或中心开展。
- 纳入7-17岁、3周导入期心理社会治疗无应答且CDRS-R评分≥45的重性抑郁障碍患者,按1:1:1:1随机分配至阿戈美拉汀10mg/日、阿戈美拉汀25mg/日、安慰剂或氟西汀(10-20mg,依症状严重程度)。
- 所有参与试验实施的人员和患者对治疗分配设盲,采用为本试验开发的标准手册化心理社会咨询,从筛选期开始并贯穿研究包括开放标签延伸期。
- 2016年2月23日至2020年1月14日评估466例,纳入400例,其中396例(247例[62%]女孩,149例[38%]男孩;平均年龄13.7岁[SD 2.7])纳入全分析集。
主要发现
- 主要终点达标:25mg/日阿戈美拉汀组(n=94)第12周CDRS-R原始分较安慰剂组(n=101)改善4.22(95%CI 0.63-7.82;p=0.040)。
- 氟西汀组(n=99)效应与阿戈美拉汀25mg/日相似,确立检测灵敏度。
- 总体效应在青少年(n=317)中确认,但在儿童(n=79)中未确认。
- 阿戈美拉汀未观察到非预期安全信号,无显著体重增加或对自杀行为的影响。
关键数值与推荐
- 主要终点为基线至第12周CDRS-R原始分变化。
- 阿戈美拉汀25mg/日组(n=94)较安慰剂组(n=101)CDRS-R原始分改善4.22(95%CI 0.63-7.82;p=0.040)。
- 阿戈美拉汀10mg/日组n=102。
- 氟西汀组n=99,效应与阿戈美拉汀25mg/日相似。
临床怎么用
- 作者认为25mg/日阿戈美拉汀联合心理社会咨询可为青少年重性抑郁障碍的有限精神药物选择提供另一种选项。
局限性
- 总体效应在青少年(n=317)中确认,但在儿童(n=79)中未确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depressive disorder is a severe illness that frequently manifests before the age of 18 years, often recurring later in life. Paediatric medical treatment options are scarce. The melatonin receptor agonist and 5-hydroxytryptamine2C receptor antagonist agomelatine is used to treat adults, and could offer a new therapeutic option for paediatric patients. Therefore, we aimed to investigate the short-term antidepressant efficacy and safety of agomelatine in children and adolescents with major depressive disorder. METHODS: We performed a 12 week, randomised, double-blind, parallel-group, multicentre, phase 3 trial in 46 specialist psychiatric units or centres in Bulgaria, Finland, Hungary, Poland, Romania, Russia, Serbia, South Africa, and Ukraine. Participants (aged 7-17 years) were eligible if they were unresponsive to psychosocial therapy during the 3-week run-in period (Children's Depression Rating Scale-revised [CDRS-R] score of ≥45). Ethnicity was not recorded. We investigated short-term antidepressant efficacy of agomelatine (10 mg or 25 mg per day) versus placebo with an active control (fluoxetine 10-20 mg depending on symptom severity) after 12 weeks of treatment in children (aged 7-11 years) and adolescents (12-17 years) with major depressive disorder. Patients were randomly assigned (1:1:1:1) to agomelatine 10 mg, agomelatine 25 mg, placebo, or fluoxetine via an interactive response system with permuted-block randomisation. Standardised manualised psychosocial counselling, developed for this trial, was initiated from selection and continued throughout the study, including the open-label extension. All people involved in the conduct of the clinical trial and patients were masked to treatment allocation. Study outcomes were measured using standardised interviews at each study visit. The primary endpoint was change in CDRS-R raw score from baseline to week 12. This study is registered with EudraCT, 2015-002181-23. FINDINGS: Between Feb 23, 2016, and Jan 14, 2020, 466 individuals were assessed for eligibility and of 400 included patients, 396 (247 [62%] girls, 149 [38%] boys; mean age 13·7 years [SD 2·7]) were analysed (full analysis set). The primary objective was met; 25 mg/day agomelatine (n=94, with n=102 receiving 10 mg/day) resulted in an improvement versus placebo (n=101) in CDRS-R raw score of 4·22 (95% CI 0·63-7·82; p=0·040) at 12 weeks, with a similar effect for fluoxetine (n=99), establishing assay sensitivity. The overall effect was confirmed in adolescents (n=317), but not in children (n=79). No unexpected safety signals were observed with agomelatine, with no significant weight gain or effect on suicidal behaviours. INTERPRETATION: This first study in a paediatric population supports the efficacy of 25 mg/day agomelatine, in addition to psychosocial counselling, in treating adolescent patients with major depressive disorder, with no unexpected safety signals. This medication could provide another option in the limited psychopharmaceutical repertoire for management of major depressive disorder. FUNDING: Servier. VIDEO ABSTRACT.
引用
- Arango C, Buitelaar JK, Fegert JM, et al. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. Lancet Psychiatry. 2021. PMID: 34919834. doi:10.1016/S2215-0366(21)00390-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。